Helene Lelievre
Suresnes, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Elevated target expression by dual PD-L1 and 4-1BB engagement is associated with 89Zr-PD-L1x4-1BB bispecific Mabcalin tumor uptake.
Journal: Theranostics
Published: January 09, 2026
The PD-L1/4-1BB Bispecific Antibody-Anticalin Fusion Protein PRS-344/S095012 Elicits Strong T-Cell Stimulation in a Tumor-Localized Manner.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: July 30, 2021
Quantitative Systems Pharmacology Approaches for Immuno-Oncology: Adding Virtual Patients to the Development Paradigm.
Journal: Clinical pharmacology and therapeutics
Published: April 08, 2020
Histone deacetylase inhibitor abexinostat affects chromatin organization and gene transcription in normal B cells and in mantle cell lymphoma.
Journal: Gene
Published: November 23, 2015
Phase 1 study of the oral histone deacetylase inhibitor abexinostat in patients with Hodgkin lymphoma, non-Hodgkin lymphoma, or chronic lymphocytic leukaemia.
Journal: Investigational new drugs
Published: October 30, 2014
Treatment of nasopharyngeal carcinoma cells with the histone-deacetylase inhibitor abexinostat: cooperative effects with cis-platin and radiotherapy on patient-derived xenografts.
Journal: PloS one
Published: November 08, 2013
The histone deacetylase inhibitor abexinostat induces cancer stem cells differentiation in breast cancer with low Xist expression.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 22, 2013
Thrombocytopenia induced by the histone deacetylase inhibitor abexinostat involves p53-dependent and -independent mechanisms.
Journal: Cell death & disease
Published: February 19, 2013
Showing 1-8 of 8
Last Updated: 09/26/2026